InsiderTrades.com logo
Eugene Williams net worth and biography
  • Phone
  • Email
  • Website

Eugene Williams Biography and Net Worth

Chairman and Co-Founder of Promis Neurosciences

Eugene Williams is a former SVP at Genzyme, with senior roles integrating commercialization, drug development, and deal making. He is also an entrepreneur, as the founder and director of Adheris, which became the largest company in the patient adherence area. He was previously a strategy consultant at Bain and Corporate Decisions Inc. (a Bain Spin off, now part of Oliver Wyman), where he was co-Head of Healthcare and spent extensive time on speeding and improving the drug development process and on commercialization strategies. Mr. Williams was most recently the CEO of Dart Therapeutics, an Orphan Disease drug development company. Mr. Williams holds a BA from Harvard University and an MBA from Harvard Business School.

What is Eugene Williams' net worth?

The estimated net worth of Eugene Williams is at least $190.42 thousand as of March 4th, 2026. Mr. Williams owns 12,397 shares of Promis Neurosciences stock worth more than $190,418 as of August 25th. This net worth approximation does not reflect any other assets that Mr. Williams may own. Learn More about Eugene Williams' net worth.

How do I contact Eugene Williams?

The corporate mailing address for Mr. Williams and other Promis Neurosciences executives is 1920 Yonge Street Suite 200, Toronto A6, M4S 3E2. Promis Neurosciences can also be reached via phone at (416) 847-6898 and via email at [email protected]. Learn More on Eugene Williams' contact information.

Has Eugene Williams been buying or selling shares of Promis Neurosciences?

Eugene Williams has not been actively trading shares of Promis Neurosciences in the last ninety days. Most recently, on Wednesday, March 4th, Eugene Williams bought 2,000 shares of Promis Neurosciences stock. The stock was acquired at an average cost of $24.00 per share, with a total value of $48,000.00. Following the completion of the transaction, the director now directly owns 12,397 shares of the company's stock, valued at $297,528. Learn More on Eugene Williams' trading history.

Are insiders buying or selling shares of Promis Neurosciences?

In the last twelve months, Promis Neurosciences insiders bought shares 6 times. They purchased a total of 710,585 shares worth more than $8,655,727.23. The most recent insider tranaction occured on April, 22nd when Director Patrick D Kirwin bought 4,000 shares worth more than $45,320.00. Insiders at Promis Neurosciences own 1.5% of the company. Learn More about insider trades at Promis Neurosciences.

Information on this page was last updated on 4/22/2026.

Eugene Williams Insider Trading History at Promis Neurosciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/4/2026Buy2,000$24.00$48,000.0012,397View SEC Filing Icon  
3/2/2026Buy1,000$22.53$22,530.007,397View SEC Filing Icon  
See Full Table

Eugene Williams Buying and Selling Activity at Promis Neurosciences

This chart shows Eugene Williams's buying and selling at Promis Neurosciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Promis Neurosciences Company Overview

Promis Neurosciences logo
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $15.36
Low: $14.50
High: $15.36

50 Day Range

MA: $13.31
Low: $10.16
High: $15.19

2 Week Range

Now: $15.36
Low: $6.27
High: $27.40

Volume

60,642 shs

Average Volume

106,621 shs

Market Capitalization

$137.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A